Th e previous issue's article on combination therapy of severe sepsis and septic shock by Diaz-Martin and colleagues [1] opens the door to discussion regarding signi fi cant advances on this issue. For the most part, scientifi c research in this fi eld over the past four decades has focused on the development of novel therapeutic targets [2] . Despite this eff ort, no therapies aimed at these novel targets are currently licensed. Current guidelines for management of sepsis provide guidance on the appropriate use of antimicrobials [3] ; however, we have only recently begun to answer some fundamental questions of how to optimize antimicrobial therapy to maximize survival in sepsis and septic shock. For example, our study of a large international cohort of septic shock patients identifi ed that the duration of hypotension prior to the administration of appropriate antimicrobials was a key determinant in survival [4] . Th e precipitous hourly decline in survival among patients inadequately treated with antimicrobials was startling. Despite this, only half of the patients in the cohort received appropriate antimicrobials in the fi rst 6 hours following the onset of hypotension. Th ese fi ndings emphasize that earlier recognition and eff ective delivery of antimicrobial therapy improve survival in patients with septic shock. Other studies in recent years have examined the potential role of optimized pharmacokinetics of antimicrobial agents in sepsis and septic shock. Both those studies and our own are predicated on the idea that faster clearance of pathogens should result in improved outcomes in severe sepsis and septic shock.
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Th is hypothesis raises the question of whether combined antimicrobial therapy could further improve survival in septic shock? In the previous issue of Critical Care, Diaz-Martin and colleagues [1] describe the eff ect of empiric combination antimicrobial therapy in patients with severe sepsis and septic shock. Th e results of this observational study, using a relatively large multicenter Spanish patient cohort, were impressive. Patients who received combination antimicrobial therapy experienced a 15% relative reduction in mortality and a 30% reduction in the odds of death when compared to patients who received single antibiotic therapy. Th e mechanisms responsible for this observed benefi t, however, are diffi cult to identify. While a synergistic eff ect with enhanced clearance of pathogens is possible, the use of more than a single antimicrobial agent could also cast a broader net to capture potentially resistant infecting pathogens with higher frequency. Further, the results could be specifi c for a single national cohort and depend on the relative diff erences in broad antimicrobial resistance.
Our recent propensity matched analysis of several thousand patients with culture-positive septic shock suggested a similar benefi t [5] . In that study, patients who received a combination of a β-lactam with either an aminoglycoside, fl uoroquinolone or macrolide/clindamycin experienced greater hospital survival, as well as reduced days in the ICU and requirements for vasoactive and
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Emerging concepts in optimizing antimicrobial therapy of septic shock: speed is life but a hammer helps too [5] . We proposed that the basis for these eff ects was due to improved pathogen eradication (additive or synergistic eff ects) rather than increased breadth of coverage because each pathogen was know to be sensitive to at least one agent utilized. Does this mean all patients with sepsis (as opposed to septic shock) should receive combination antimicrobial therapy? It appears that 'one size may not fi t all' . We examined this question using pooled data from 62 datasets extracted from 50 published studies on antimicrobial therapy in severe bacterial infections [6] . While no overall benefi t was found when we directly compared patients receiving combination versus monotherapy, we observed a dichotomous eff ect when patients were stratifi ed by their risk of death. Among patients with a likelihood of death greater than 15%, combination therapy reduced the odds of death by nearly 50% when compared to patients receiving monotherapy. Th e eff ect was particu larly pronounced in patients with septic shock. On the other hand, a recent randomized multicenter trial in Germany comparing combination antimicrobial therapy with meropenam and moxifl oxacin versus meropenam alone further complicates this issue [7] . No survival diff erence was seen between groups treated early for severe sepsis. How can we reconcile these disparate results?
We suggest the question is more complex than one of simple monotherapy versus combination therapy. Th e key issue may be the ability of combination therapy to augment bacterial clearance compared to monotherapy. If so, it is likely that augmented bacterial clearance with combination therapy may only be clinically relevant when the β-lactam component of combination therapy is less than maximally potent. Th e majority of pathogens causing septic shock are relatively sensitive to agents such as extended spectrum penicillins and fi rst and second generation cephalosporins, which often achieve sub-maximal bacterial clearing with 60 to 70% time above the minimal inhibitory concentration (T>MIC) of the pathogen in the plasma. While this is adequate to improve survival for many serious infections, there is evidence to suggest that 100%T>MIC may result in more eff ective clearance [8] . Th e use of high potency carbapenems will generate a time >MIC of 100% and maximally rapid bacterial clearance for all but a few relatively resistant pathogens such as Pseudomonas. A second agent would not be expected to increase bacterial clearance (and correspondingly fail to improve outcome) in this circumstance.
Indeed, this insensitivity to combination therapy for regimens that included carbapenems was noted in our own analysis [5] . Benefi cial eff ects of combination therapy were limited to regimens that utilized less than maximally potent antimicrobials, such as extended penicillins (for example, ampicillin, ticarcillin, pipercillin), semisynthetic penicillins (cloxacillin, oxacillin, and so on), as well as fi rst, second and third generation (nonpseudo monal) cephalosporins. Agents with maximal potency in terms of T>MIC for the majority of septic shock pathogens (carbapenems, ticarcillin/clavulanate, pipera cillin/tazobactam, ceftazidime) yielded no benefi t with the addition of a supplemental antibiotic.
Further study is clearly needed to address the question of under what circumstances combination therapy may be useful in sepsis and septic shock. Such a study should address shortcomings in the current extensive database of studies in this area. In particular, rather than asking the question of whether a specifi c antimicrobial combination is superior to a specifi c monotherapy in a specifi c infection within a relatively uniform microbial environment, a pragmatic study utilizing diff erent commonly used antibiotic combinations in a variety of clinical conditions resulting in severe sepsis or septic shock would be most useful. In addition and perhaps most importantly, the specifi c logistics of the study should be developed on the basis of an underlying hypothesis of why combination antimicrobial therapy may be useful.
We suggest that the study should be designed based on the concept that enhanced bacterial clearance using synergistic drug combinations in septic shock will yield faster time to hemodynamic stability and improved survival. Th is suggests that the study would have to be done in an environment where the standard of therapy currently yields less than maximally rapid bacterial clearance (so that the addition of a supplemental agent could reasonably enhance bacterial clearance in a reasonable subset of cases). Th is could either be midlevel microbial resistance environments where agents such as high potency β-lactam/β-lactamase inhibitor combinations and carbapenems for empiric therapy of severe sepsis/septic shock are not routinely utilized. Alternatively, the use of combination therapy with highly potent agents should, in theory, be of potential benefi t in high microbial resistance environments. A prospective randomized study of this sort in combination with appropriate supplemental sub-studies of bacterial clearance would likely provide a defi nitive answer to the persistent question of the relative benefi t of combination versus monotherapy in the critically ill patient with severe sepsis or septic shock.
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